GT Biopharma expands private placement to $5.95M, adds new investor Marzilli

GT Biopharma, Inc.

Increased Series L preferred offering to 6,612 shares ($5.95M) from 6,056 shares ($5.45M) via First Amendment on May 21, 2025.
Added Robert A. Marzilli as new purchaser; Majority Purchasers (Five Narrow Lane, Bristol Capital) consented.
Filed Certificate of Increase raising authorized Series L shares from 28,056 to 30,630.
Greenshoe right: Purchasers may buy up to $24.0M additional preferred stock on same terms.

item 1.01item 3.02item 3.03item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.